Recently, immune checkpoint inhibitors (ICIs) targeting immune checkpoints, especially programmed cell death-1 (PD-1) and its ligand (PD-L1), have shown encouraging results in several cancer types [3]. The gene discussed is PDCD1; the disease is cancer.